Alivus Life Sciences Posts Strong Q2 FY27 Results, Revenue Grows 16% YoY, PAT Jumps 51.3%
Mumbai: Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, announced its financial results for the second quarter and half-year ended September 30, 2026, on October 29, 2026. Financial Highlights Revenue from operations for Q2 FY27 stood at ₹682 crore, growing 16.0% YoY. The non-GPL business contributed significantly, with a 20.8% YoY growth. EBITDA for Q2 FY27 was ₹285.1…
Mumbai-based Alivus Life Sciences Limited, formerly known as Glenmark Life Sciences Limited, released its Q2 FY27 and H1 FY27 financial results on October 29, 2026. Q2 FY27 revenue from operations reached ₹682 crore, a 16.0% year-over-year increase. The non-GPL business drove growth with a 20.8% YoY rise. EBITDA for Q2 FY27 amounted to ₹285.1 crore, a 47.0% YoY surge, with margins improving to 41.8%.
PAT for the quarter hit ₹196.8 crore, a 51.3% YoY jump, marking a 28.9% margin, up 680 basis points from the previous year. For H1 FY27, revenue was ₹1,322.4 crore, an 11.1% YoY gain, with EBITDA at ₹519.2 crore, up 38.4% YoY, and margins at 39.3%. The company generated ₹270.2 crore in free cash flow, bringing cash and cash equivalents to ₹1,011.6 crore as of September 30, 2026.
Alivus Life Sciences had 630 DMF/CEP filings as of that date. In Q2 FY27, MD & CEO Yasir Rawjee highlighted strong revenue growth and healthy demand, while CFO Tushar Mistry emphasized robust cash generation. The company filed 10 patents in H1 FY27, securing 3, bringing total patent grants to 88 as of September 30, 2026. Zydus Lifesciences is investing over ₹166 crore in Sri Lanka manufacturing facilities and advancing R&D projects in Solapur and Taloja, Navi Mumbai.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
